Alerta

Continuous detection glucometer for intensive care department

Resumen de: CN120369948A

The invention belongs to the technical field of blood glucose detection, and particularly relates to a continuous detection blood glucose meter for the intensive care department, which comprises a transparent shell, the shell comprises an upper shell and two lower shells, the right parts of the lower shells are provided with finger grooves, the left part of the shell is provided with a blood glucose detector, and a translation rod driven by a driving mechanism is arranged below the blood glucose detector; and the right end of the translation rod is connected with a push block extending into the shell. A finger is placed in a finger groove, blood is taken through a blood taking needle, the finger is pressed through a pressing block, a translation rod, a pushing block and a moving block are controlled to move leftwards, a blood glucose detection plate with sucked blood is driven to be inserted into a blood glucose detector, and other blood glucose detection plates are limited through two pairs of limiting parts; and the translation rod, the push block and the moving blocks are controlled to move rightwards, the used blood glucose detection plate is taken out, then the translation rod and the push block are reset, the next moving block is embedded into the placement groove, automatic replacement of the blood glucose detection plate is completed, repeated blood glucose detection is continuously carried out, and the blood glucose detection efficiency is improved.

Insulin loading and unloading needle device

Resumen de: CN223143897U

The utility model discloses an insulin loading and unloading needle device which comprises a sleeve, two through holes are symmetrically formed in the two side walls of the sleeve, an elastic pressing edge is installed in each through hole, a pressing head is installed on the lower portion of the outer wall of each elastic pressing edge, and a limiting head is installed on the lower portion in each elastic pressing edge. A through hole is formed in the middle of the inner bottom end of the sleeve, and four limiting tables are annularly distributed on the periphery of the inner bottom end of the sleeve. The insulin injection pen needle has the advantages that on one hand, the outer needle cap can be effectively limited under the action of the through hole, the elastic clamping edge, the pressing head and the limiting head, rapid separation of the insulin injection pen needle and the outer needle cap during installation is achieved, and on the other hand, the insulin injection pen needle can be shielded and protected during disassembly under the action of the sleeve; and the insulin injection pen needle head is prevented from accidentally injuring hospital personnel during disassembly, so that the safety during disassembly of the insulin injection pen needle head is better.

Insulin pump protection device

Resumen de: CN223143876U

The utility model belongs to the technical field of insulin pumps, and particularly relates to an insulin pump protection device which comprises an insulin pump body. A fixing assembly is arranged on the side wall of the insulin pump body; the insulin pump body is connected with a protection box body through a fixing assembly. The insulin pump body is placed in the protection box body; the side wall of the protection box body is fixedly connected with an air bag strip. A plurality of groups of air bag strips are arranged on the side wall of the protection box body and are uniformly distributed at the edges of the protection box body; according to the step, through the arrangement of a protection box body, an air bag strip, an air bag ball, a first sponge block, a cover plate and a second sponge block, the insulin pump body is placed and fixed in the insulin pump body, the situation that the insulin pump body falls to cause damage to the insulin pump body is reduced, and the situation that the insulin pump body is damaged when extruded is reduced; the service life of the insulin pump body is prolonged, and the use safety of the device is improved.

Automatic blood glucose detection instrument

Resumen de: CN120360549A

The invention discloses an automatic blood glucose detection instrument, and relates to the technical field of medical equipment, the automatic blood glucose detection instrument comprises an operation table and a blood glucose meter body, the side wall of the operation table is provided with a storage box, the two side walls of the blood glucose meter body are provided with loudspeakers, and the top of the blood glucose meter body is fixedly provided with a turnover mechanism; and a mounting cylinder is inserted into the top of the turnover mechanism. Through the arrangement of the abutting ball, the two spring columns, the two fixing rods, the measuring spring, the two abutting springs, a reset assembly and a fixing disc, the stretching length of the puncture needle is adjusted in a self-adaptive mode according to the skin thickness of a patient, multiple puncture tests are not needed, puncture wounds of the patient are reduced, the infection risk is reduced, operation is easy, convenient and rapid, and the device is worthy of popularization and has a wide application prospect. And through the arrangement of a one-way spring, two wedge-shaped blocks, a plurality of triangular grooves and an insertion column, the puncture of the puncture needle is not influenced when the insertion column is reset every time.

Systems and methods for distributing continuous glucose data

Resumen de: AU2025205069A1

MARKED-UP COPY The present disclosure relates to systems, devices and methods for receiving biosensor data acquired by a medical device, e.g., relating to glucose concentration values, and controlling the access and distribution of that data. In some embodiments, systems and methods are disclosed for monitoring glucose levels, displaying data relating to glucose values and metabolic health information, and controlling distribution of glucose data between applications executing on a computer, such as a smart phone. In some embodiments, systems and methods are disclosed for controlling access to medical data such as continuously monitored glucose levels, synchronizing health data relating to glucose levels between multiple applications executing on a computer, and/or encrypting data. The present disclosure relates to systems, devices and methods for receiving biosensor data acquired by a medical device, e.g., relating to glucose concentration values, and controlling the access and distribution of that data. In some embodiments, systems and methods are disclosed for monitoring glucose levels, displaying data relating to glucose values and metabolic health information, and controlling distribution of glucose data between applications executing on a computer, such as a smart phone. In some embodiments, systems and methods are disclosed for controlling access to medical data such as continuously monitored glucose levels, synchronizing health data relating to glucose levels between

NEUROMODULATION SYSTEM TO INDUCE CHANGES IN GLYCEMIC REGULATORY SYSTEM PLASTICITY

Resumen de: AU2023420510A1

Current Type 2 Diabetes Mellitus treatments include life-style management, pharmaceuticals and may include bariatric surgery for the morbidly obese. However, issues with compliance, side effects and permanent anatomical alterations provide a need for an alternative therapy to modulate a peripheral nerve, such as the vagus nerve, in a manner that causes a plastic change in the glycemic regulatory system, with or without the involvement of the central nervous system (CNS), that changes the activity of an organ and thereby changing the activity of that organ. Low energy vagus nerve neuromodulation has potential as a new treatment for type 2 diabetes mellitus by inducing plasticity of the body's glycemic regulatory system with low energy transient stimulation. This will allow for effective use of a small implantable pulse generator that requires infrequent, or no, charging during the life of the device.

SELF-INSERTING TROCARLESS ANALYTE-SENSING CANNULA

Resumen de: AU2024209583A1

The disclosure describes devices and methods for insertion and delivery of insulin or an insulin analog formulation and measurement of subcutaneous glucose concentration. A device for delivery of insulin or an insulin analog formulation and measurement of subcutaneous glucose concentration, may comprise: (a) a tube comprising a proximal end and a distal end, wherein the proximal end is in fluid communication with a source of the insulin or insulin analog formulation, and wherein the distal end is configured to deliver the insulin or insulin analog formulation subcutaneously; (b) a glucose sensor disposed along a central axis of the tube; and (c) a penetrating body disposed along the central axis of the tube, wherein the penetrating body comprises a cross-sectional area no more than a cross-sectional area of the glucose sensor.

INSULIN DOSAGE DETERMINATION SYSTEM BASED ON PERSONALIZED ARTIFICIAL INTELLIGENCE

Resumen de: US2025239350A1

Provided is a personalized artificial intelligence-based insulin dose determination system includes an interface layer capable of communicating with the insulin pump and the continuous blood glucose system, and signal-processing information from the insulin pump and the continuous blood glucose system, a control layer receiving the signal-processed information from the interface layer and generating output information associated with an insulin infusion amount, an outer safety layer determining whether or not the output information generated from the control layer satisfies a preset threshold condition, and delivering the output information to the interface layer when the output information satisfies the preset threshold condition, and a personalized safety layer receiving prescription information including Total Daily Dose of Insulin (TDD) information of the user from the outside to determine a personalized safety control variable, and transmitting the determined control variable as an input variable of the control layer.

GLUCOSE SENSOR FOR GLYCEMIC ASSESSMENT

Resumen de: US2025235100A1

An analyte assessment system includes an analyte sensor, a remote device, and a software application. The remote device is configured to retrieve sensor data of a patient from the analyte sensor. The software application is configured to receive an order for analyte assessment associated with an electronic medical record (EMR) of the patient, generate or retrieve a unique identifier associated with the order, authenticate the unique identifier with the remote device, activate the analyte sensor based on the unique identifier, retrieve sensor data from the remote device, generate a report, and upload the report to the EMR of the patient. Advantageously the system can streamline requests and delivery of analyte reports for third parties, reduce in-person patient interactions and time delays, reduce third party effort, increase security and integrity of patient data, update an EMR of the patient, and operate in a blinded mode for unbiased patient analyte assessment.

SIGNAL QUALITY ASSESSEMENT SYSTEM AND BLOOD GLUCOSE LEVEL PREDICTION SYSTEM BASED ON PHOTOPLETHYSMOGRAPHY

Resumen de: US2025235127A1

The present invention relates to a signal quality assessment system and a blood glucose level prediction system based on photoplethysmography. The signal quality assessment system comprises a near-infrared light photoplethysmography sensor, a Bluetooth module, an AI acceleration platform, and an electronic device. The AI acceleration platform serves as the central analysis unit, receiving PPG signals from the front-end sensing unit via an interface. Signal processing, including bandpass filtering composed of high-pass and low-pass filters and data normalization, is executed by the processor. Configurable AI chips are used to evaluate the quality of PPG signals, facilitating the discard of unwanted signals and subsequent reconstruction for blood glucose assessment. Processed PPG signals and the corresponding assessed blood glucose values are transmitted to a display. The display provides a comprehensive and real-time view of the monitored data, enabling efficient and timely interpretation of blood glucose values.

UNIFIED PLATFORM FOR MONITORING AND CONTROL OF BLOOD GLUCOSE LEVELS IN DIABETIC PATIENTS

Resumen de: US2025235155A1

A flexible system for utilizing data from different monitoring techniques and capable of providing assistance to patients with diabetes at several scalable levels, ranging from advice about long-term trends and prognosis to real-time automated closed-loop control (artificial pancreas). These scalable monitoring and treatment strategies are delivered by a unified system called the Diabetes Assistant (DiAs) platform. The system provides a foundation for implementation of various monitoring, advisory, and automated diabetes treatment algorithms or methods. The DiAs recommendations are tailored to the specifics of an individual patient, and to the patient risk assessment at any given moment.

ANALYTE AND ENVIRONMENT SENSORS

Resumen de: US2025235131A1

Disclosed are devices, systems and methods for in vivo monitoring of localized environment conditions within a patient user by measuring analytes, including glucose, oxygen, and/or other analytes. In some aspects, a sensor device includes a wafer-based substrate, at least one electrochemical sensor two-electrode contingent including a working electrode and a reference electrode on the substrate and configured to detect a target analyte in a body fluid when the sensor device is deployed within a subject's body, where the working electrode is functionalized by a chemical layer configured to facilitate a reaction involving the target analyte that produces an electrical signal; and an electronics unit in communication with the electrochemical sensor electrode contingent to transmit the electrical signal to an external processor.

CLOSED-LOOP ARTIFICIAL PANCREAS INSULIN INFUSION CONTROL SYSTEM

Resumen de: US2025235609A1

A closed-loop artificial pancreas insulin infusion control system is provided. The system includes a detection module configured to detect the current blood glucose level G continuously, a program module configured to preset with an rPID algorithm that converts the asymmetric blood glucose in the original physical space to the approximately symmetric blood glucose risk in the risk space and target blood glucose level, and an infusion module which is connected to and controlled by the program module and is configured to infuse insulin according to the corresponding output instructions calculated by the rPID algorithm. The simple and robust characteristics of PID algorithm can be retained, and giving the rPID algorithm the advantages of precision and flexibility, realizing precise control for closed-loop artificial pancreas insulin infusion system.

CLOSED-LOOP ARTIFICIAL PANCREAS INSULIN INFUSION CONTROL SYSTEM

Resumen de: US2025235606A1

The invention discloses a closed-loop artificial pancreas insulin infusion control system, including: a detection module and an infusion module, a detection control unit is set in the detection module, an infusion control unit is set in the infusion module, and at least one calculation control unit is set in the detection module and the infusion module for calculating insulin infusion information and/or further processing of different insulin infusion information. Therefore, the closed-loop artificial pancreas insulin infusion control system can automatically switch the control unit according to different situations to avoid affecting the user experience due to the failure of a module or even bringing safety risks to the user, and to avoid replacing the whole device when only part of the function of some components fails, and to improve the utilization rate of each component of the closed-loop artificial pancreas.

SYSTEMS AND METHODS OF MONITORING A CATHETER OR SHUNT DEVICE AND FLUID OF THE SYSTEM

Resumen de: US2025235675A1

A monitoring system is provided. The monitoring system includes a controller and either a shunt device, an externally-communicating catheter, and/or a fluid retention device. The shunt device and catheter are configured to address fluid movement such as ascites and pleural effusions. Each of the shunt device and catheter include a plurality of sensors that communicate with the controller positioned external to a body of a subject. The plurality of sensors are configured to output a signal indicative of a total volume, a glucose amount, or an oxygenation within a fluid flowing in contact within or surrounding the shunt device or the catheter.

METHOD FOR INCREASING ACCURACY AND PRECISION OF NON-INVASIVE BLOOD GLUCOSE MEASUREMENT APPARATUS

Resumen de: WO2025154863A1

The present invention relates to a method for increasing the accuracy and precision of a non-invasive blood glucose measurement apparatus and, more specifically, to a method for increasing the accuracy and precision of a non-invasive blood glucose measurement apparatus, wherein, in order to increase the accuracy and precision of quantitative analysis of the non-invasive blood glucose measurement apparatus, an algorithm having a qualitative analysis and an algorithm of quantitative analysis are combined to enhance blood glucose prediction values. To this end, the present invention comprises: a step of starting measurement after making contact with the capillary system in the skin of the body by using a selected wavelength band related to blood glucose; a skin irradiation step of sequentially irradiating the blood vessels in the skin with monochromatic light corresponding to each of visible light and near-infrared light; and a detector signal step of a detector receiving signals from the monochromatic light in the skin irradiation step, wherein the detector signal step is completed, and the accuracy and precision of the non-invasive blood glucose measurement apparatus are increased.

PERSONALIZED ARTIFICIAL INTELLIGENCE-BASED INSULIN DOSE DETERMINATION SYSTEM

Resumen de: WO2025154971A1

Provided is a personalized artificial intelligence-based insulin dose determination system for a terminal which can communicate with an insulin pump and a continuous blood glucose meter used by a user, the personalized artificial intelligence-based insulin dose determination system comprising: an interface layer which can communicate with the insulin pump and the continuous blood glucose meter, and signal-processes information from the insulin pump and the continuous blood glucose meter; a control layer which receives the signal-processed information from the interface layer and generates output information associated with an insulin injection amount; an outer safety layer which determines whether the output information generated from the control layer satisfies a preset threshold value condition, and if the output information satisfies the preset threshold value condition, transfers the output information to the interface layer; and a personalized safety layer which determines a safety control variable per individual by receiving, from the outside, prescription information including the total daily dose (TDD) of insulin information of a user, and transmits the determined control variable as an input variable of the control layer.

LASER BLOOD COLLECTION AND BLOOD GLUCOSE MEASUREMENT DEVICE

Resumen de: WO2025155053A1

The present invention relates to a laser blood collection and blood glucose measurement device. The laser blood collection and blood glucose measurement device comprises: an examinee identification unit for outputting identification information about examinees; a storage unit for storing examinee information corresponding to each piece of identification information and the laser intensity levels corresponding to the respective examinees; an operation control unit connected to the examinee identification unit and the storage unit; a capacitor module unit connected to the operation control unit and including a capacitor; and a laser output module unit that is connected to the capacitor module unit and outputs a laser of a corresponding intensity to the skin of the current examinee according to the charging voltage applied from the capacitor module unit, thereby causing bleeding. The operation control unit is connected to the examinee identification unit, identifies the examinee corresponding to the identification information applied from the examinee identification unit among the examinees stored in the storage unit and stores the examinee as the current examinee in the storage unit, determines the laser intensity level corresponding to the current examinee among the laser intensity levels stored in the storage unit, and controls the charging voltage of the capacitor according to the determined laser intensity level.

CLOSED-LOOP ARTIFICIAL PANCREAS INSULIN INFUSION CONTROL SYSTEM

Resumen de: US2025235614A1

A closed-loop artificial pancreas insulin infusion control system is provided. The system includes a detection module configured to detect the current blood glucose level G continuously, a program module connected to the detection module and preset with a hybrid artificial pancreas algorithm, used for calculating the insulin infusion amount required by the user, the hybrid artificial pancreas algorithm includes a cPID algorithm and/or a cMPC algorithm, where the input of the cPID algorithm is the intermediate value of the MPC algorithm, and the input of the cMPC algorithm is the output value of the PID algorithm, and an infusion module connected to the program module and controlled by the program module to infuse insulin according to the insulin infusion amount calculated by the hybrid artificial pancreas algorithm.

MANAGEMENT DEVICE AND METHOD FOR DISPLAYING GLUCOSE INFORMATION

Resumen de: WO2024055249A1

A management device for displaying glucose information. The screen of the management device is divided into the plurality of display areas, at least comprising a first display area for displaying the status of the management device, a second display area for displaying real-time glucose information, and a third display area for displaying historical glucose concentration information. The user can intuitively and easily get the glucose information in the body.

DRUG INFUSION SYSTEM WITH GRAPHICAL USER INTERFACE

Resumen de: EP4588494A1

The invention discloses a drug delivery system with graphical user interface comprises detection device, for detecting the blood glucose level of the user; an infusion device, for infusing a drug into the user's body; and a control device, wirelessly communicated with the detection device and the infusion device, the control device controlling the drug delivery of the infusion device, and the control device provided with a graphical user interface, the graphical user interface comprising a main screen, the main screen comprising an insulin information display area and a blood glucose information display area, wherein the insulin information display area comprising insulin infusion status information, the graphical user interface displays the insulin infusion status information in a graphical and/or textual manner, to facilitate the user to intuitively know the insulin infusion status information and blood glucose information at that time.

SYSTEMS AND METHODS FOR DIABETES MANAGEMENT

Resumen de: CN119856162A

Systems, devices, and methods are provided for incorporating a drug delivery device into an integrated management system. The integrated management system may be an integrated diabetes management system and may include a glucose monitor, a connected insulin pen, and software. An integrated management system may generate a plurality of reports, which may include data related to analyte levels (e.g., glucose levels) and delivered drugs (e.g., delivered insulin). The integrated system may also include a mode in which certain types of data are no longer shared and/or stored if the user does not log in the account. The type of data shared and/or stored when the user does not log in the account may be different from the type of data shared and/or stored when the user logs in the account.

ADJUSTING INSULIN DELIVERY RATES

Resumen de: EP4588437A2

The present disclosure relates to a diabetes management system and a method for the same. The system includes a pump device and a controller, where the controller is in electrical communication with a drive system for controlling dispensation of insulin from an insulin cartridge. The controller, over a first diurnal time period, communicates electrical control signals to the drive system to cause insulin to be dispensed based on a baseline basal insulin rate that is stored. The controller also receives at least blood glucose data to control dispensation of insulin in amounts variable from the baseline basal insulin rate. Additionally, the controller modifies the baseline basal insulin rate that is stored for a second diurnal time period that is at least 20 hours after the first diurnal period, based on an amount of insulin actually dispensed during the first diurnal time period.

Implantable wireless passive chemical sensor system and preparation method and application thereof

Resumen de: CN120345895A

The invention belongs to the technical field of biosensing, and particularly relates to an implantable wireless passive chemical sensor system as well as a preparation method and application thereof. The sensor system comprises a miniature implantable sensor unit and a wearable relay coil network used for signal integration. Wherein the miniature implantable sensor unit adopts a three-module integrated framework, namely, the miniature implantable sensor unit comprises a chemical sensing module consisting of a miniature sensing electrode pair with potential response, a signal modulation module consisting of a variable capacitance diode pair which is connected back to back, and a wireless transmission module consisting of a spiral coil; the wearable relay network is a conductive coil network formed by embroidering a conductive wire or depositing and printing a conductive material on a flexible fabric substrate and patterning, and is used for realizing collaborative acquisition of chemical signals of multiple sensors; the system can synchronously monitor various biochemical indexes such as glucose, electrolyte, neurotransmitter and the like in body fluid and biological tissues in real time, and has important application value in the fields of wearable medical monitoring and implantable diagnosis.

Reading amplification assembly and insulin pen with same

Nº publicación: CN223127011U 22/07/2025

Solicitante:

TAIHE HOSPITAL OF TRADITIONAL CHINESE MEDICINE
\u592A\u548C\u53BF\u4E2D\u533B\u9662

Resumen de: CN223127011U

The utility model discloses a reading amplification assembly and an insulin pen with the same, and relates to the technical field of insulin syringes. The multifunctional pen comprises a pen body and a reading amplification assembly, a digital display part is arranged on the peripheral side of the pen body, a mounting seat is fixedly mounted at the digital display part on the peripheral side of the pen body, the supporting plate is detachably matched with the mounting seat, the reading amplification assembly comprises a mounting plate and two supporting plates, and the two ends of the mounting plate are hinged to one ends of the two supporting plates respectively; a through hole is formed in the surface of the mounting plate, and a lens is mounted in the through hole. According to the insulin pen, the installation base is arranged on the pen body of the insulin pen, the reading amplification assembly is detachably installed on the installation base, the reading amplification assembly comprises the magnifying lens, when the reading amplification assembly is installed, the reading of the digital display portion of the pen body can be amplified, and observation of a patient with vision decline is facilitated; after the reading amplification assembly is detached, the insulin pen can be used for normal observation and is convenient to carry and use.